Tylvalosin tartrate | CAS#63428-13-7 | Macrolide antibiotic

MedKoo Cat#: 464768 | Name: Tylvalosin tartrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tylvalosin is a macrolide antibiotic. It is active against S. aureus, E. coli, and P. multocida (MICs = 2, 128, and 128 µg/ml, respectively). Tylvalosin (5 and 10 µg/ml) reduces LPS-induced production of pro-inflammatory cytokines, prostaglandin E2 (PGE2), and nitric oxide in RAW 264.7 cells. It reduces the severity of lung lesions in pigs infected with M. hyopneumoniae and P. multocida when administered at a dose of 10 mg/kg per day in the drinking water. Formulations containing tylvalosin have been used in the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae in pigs.

Chemical Structure

Tylvalosin tartrate

CAS#63428-13-7 (tartrate)

Theoretical Analysis

MedKoo Cat#: 464768

Name: Tylvalosin tartrate

CAS#: 63428-13-7 (tartrate)

Chemical Formula: C57H93NO25

Exact Mass: 0.0000

Molecular Weight: 1192.35

Elemental Analysis: C, 57.42; H, 7.86; N, 1.17; O, 33.55

Price and Availability

Size	Price	Availability
50mg	USD 90.00	Ready to ship
100mg	USD 150.00	Ready to ship
200mg	USD 250.00	Ready to ship
500mg	USD 550.00	2 weeks
1g	USD 950.00	2 Weeks
5g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

63428-13-7 (tartrate) 63409-12-1 (free base) 63428-14-8 (HCl) 1453840-14-6 (phosphate)

Synonym

Tylvalosin tartrate; Acetylisovaleryltylosin tartrate;

IUPAC/Chemical Name

(2S,3S,4R,6S)-6-(((2R,3S,4R,5R,6R)-6-(((4R,5S,6S,7R,9R,11E,13E,15R,16R)-4-acetoxy-16-ethyl-15-((((2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-6-yl)oxy)-4-(dimethylamino)-5-hydroxy-2-methyltetrahydro-2H-pyran-3-yl)oxy)-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate (2R,3R)-2,3-dihydroxysuccinate

InChi Key

OLLSDNUHBJHKJS-XKORHJEPSA-N

InChi Code

InChI=1S/C53H87NO19.C4H6O6/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3;5-1(3(7)8)2(6)4(9)10/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3;1-2,5-6H,(H,7,8)(H,9,10)/b18-17+,28-22+;/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-;1-,2-/m11/s1

SMILES Code

OC([C@@H]([C@H](C(O)=O)O)O)=O.CN([C@@H]([C@@H]1O[C@H]2C[C@@]([C@@H](OC(CC(C)C)=O)[C@H](C)O2)(C)O)[C@@H](O)[C@H](O[C@H]3[C@@H](CC=O)C[C@@H](C)C(/C=C/C(C)=C/[C@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)[C@@H](CC)OC(C[C@@H](OC(C)=O)[C@@H]3C)=O)=O)O[C@@H]1C)C

Appearance

Solid powder

Purity

>80% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C21B07B30

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Tylvalosin tartrate (Acetylisovaleryltylosin tartrate) is a macrolide antibiotic that can against Gram-positive bacteria.

In vitro activity:

TBD

In vivo activity:

Clinical signs of the disease were more evident in the untreated group than in the treated group. The average daily weight gain, average daily feed consumption and feed conversion efficiency were better in the treated group. The combined length of intestine with lesions was 2847 cm in the untreated group and 183 cm in the treated group. The tylvalosin treatment significantly reduced the level of L intracellularis infection; almost half of the treated pigs were IHC-negative compared with 3.3 per cent of the untreated pigs. Reference: Guedes RM, França SA, Machado GS, Blumer MA, da Costa Cruz EC Jr. Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. doi: 10.1136/vr.165.12.342. PMID: 19767637.

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	25.16
	DMSO	30.0	25.16
	Ethanol	30.0	25.16

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,192.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Guedes RM, França SA, Machado GS, Blumer MA, da Costa Cruz EC Jr. Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. doi: 10.1136/vr.165.12.342. PMID: 19767637.

In vitro protocol:

TBD

In vivo protocol:

1: Guedes RM, França SA, Machado GS, Blumer MA, da Costa Cruz EC Jr. Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. doi: 10.1136/vr.165.12.342. PMID: 19767637.